The 12 closest competitors and alternatives to Disc Medicine, Inc. among biotechnology companies — ranked by similarity to what Disc Medicine, Inc. actually does, not by market-cap band.
Subscribe to see Disc Medicine, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Disc Medicine, Inc. is a biotechnology company headquartered in Watertown, United States. It is publicly listed (IRON) with a market capitalisation of $2.4B. Xcout tracks 25 named people at Disc Medicine, Inc., including John D. Quisel (Chief Executive Officer, President & Director). Xcout recorded 23 job postings from Disc Medicine, Inc. in the last 90 days.
19 more named people on record for Disc Medicine, Inc., with roles, board committees and tenure — see the full roster →
Xcout recorded 23 job postings from Disc Medicine, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Disc Medicine, Inc.'s hiring signals →
Ranked by semantic similarity — how close each company is to Disc Medicine, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Biotech
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Biotech
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
Similar biotechnology company
Sidero Bioscience is a clinical-stage biotechnology company that develops natural iron supplement products to address iron deficiency and nutritional health. Its proprietary SideroSorb platform and BioFe iron complex utilize a unique uptake mechanism designed to improve absorption and minimize gastrointestinal side effects compared to traditional iron therapies.
Similar biotechnology company
Ferrosa Therapeutics AG is a Swiss biotechnology company founded in Basel, Switzerland, focusing on developing novel therapeutics to treat anemia and related conditions.
Biotech
Remix Therapeutics, Inc. is a biotechnology company headquartered in Watertown, Massachusetts. The company specializes in developing novel therapies that alter RNA processing to address serious diseases.
Biotech
DynamiCure Biotechnology is a life sciences company applying innovative approaches to drug discovery from its facilities in Waltham, Massachusetts.
Similar biotechnology company
EpimedX LLC is an early-stage biotechnology company based in Oklahoma City, Oklahoma, that is developing novel gene regulation and drug therapies to treat blood diseases such as sickle cell disease, beta-thalassemia, and malaria.
Similar biotechnology company
Rallybio is a clinical-stage biotechnology company that develops therapies for patients with severe and rare diseases, focusing on areas such as complement dysregulation and hematology. The company's pipeline includes therapeutic assets like C5 inhibitors designed to address significant unmet medical needs.
Similar biotechnology company
Soufflé Therapeutics, Inc. is a biotechnology company headquartered in Watertown, Massachusetts. The company focuses on redefining traditional medicine discovery and development through innovative research methodologies.
Similar biotechnology company
Falcon Bio is a drug discovery company headquartered in Boston, Massachusetts, focused on targeting the root cause of cellular dysfunction to treat Friedreich's ataxia patients.
Similar biotechnology company
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Disc Medicine, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →